Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
- Share this website :
Resource Centre for HCPs
Recent advances
Myelodysplastic Syndrome (MDS)
Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
Molecular International Prognostic Scoring System
for Myelodysplastic Syndromes
Emerging treatment options for patients with high-risk myelodysplastic syndrome
Revised international prognostic scoring system for myelodysplastic syndromes
Useful links
AML Hub
MPN Hub
MDS Hub
European LeukemiaNet
American Society of Haematology
The European Haematology Association (EHA)
British Society of Haematology (BSH)
National Comprehensive Cancer Network (NCCN) ®
The Hong Kong Society of Haematology
Singapore Society of Haematology
Malaysian Society of Haematology
The Hematology Society of Taiwan
The Thai Society of Hematology
